stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Shares outstanding
Arrowhead Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $133.8M, up 11.7% from $119.8M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $143.4M. Over the past ten years it has ranged from $57.4M (fiscal 2015) to $133.8M (fiscal 2025) — the current reading is the highest in ten years. Arrowhead Pharmaceuticals, Inc. ranks 85th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $133.8M | 11.67% |
| FY2024 | $119.8M | 12.21% |
| FY2023 | $106.8M | 1.26% |
| FY2022 | $105.4M | 1.62% |
| FY2021 | $103.7M | 3.00% |
| FY2020 | $100.7M | 2.14% |
| FY2019 | $98.6M | 17.90% |
| FY2018 | $83.6M | 13.18% |
| FY2017 | $73.9M | 21.04% |
| FY2016 | $61.1M | 6.44% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $143.4M | 0.67% |
| Mar 2026 | $142.4M | 1.22% |
| Dec 2025 | $140.7M | 5.19% |
| Sep 2025 | $133.8M | (3.80%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| ARWR Arrowhead Pharmaceuticals, Inc. | $143.4M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| CORT Corcept Therapeutics Incorporated compare | $123.2M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement